Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| DSIP (Delta Sleep-Inducing Peptide) | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | 30-60 minutes before desired sleep onset. Evening only. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 2-4 week cycles with equal rest periods to prevent tolerance. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit brain hypothalamus in 1977. It modulates GABAergic neurotransmission by potentiating GABA-activated currents in hippocampal and cerebellar neurons while blocking NMDA-activated potentiation in cortical neurons. It also interacts with opioid-associated receptors, modulates serotonin and dopamine systems (increasing serotonin levels), and promotes delta wave (slow-wave) sleep through mechanisms that remain incompletely characterized.
Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal.
30-60 minutes before desired sleep onset. Evening only.
2-4 week cycles with equal rest periods to prevent tolerance.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →